Eli Lilly's lepodisiran small interfering RNA therapy Phase 2 clinical results are positive for treating hereditary heart disease
I'm PortAI, I can summarize articles.
Eli Lilly announced on March 30, 2025, that lepodisiran achieved positive results in the Phase 2 ALPACA clinical study. The therapy significantly reduced levels of the hereditary cardiovascular risk factor Lp(a), with a maximum reduction of 93.9%. The study showed that after receiving different doses of lepodisiran, patients' Lp(a) levels continued to decrease over nearly 18 months, with some patients experiencing effects lasting up to 1.5 years
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments